IRIS Accounts Production v24.3.2.46 05849628 Board of Directors 1.7.23 30.6.24 30.6.24 false true false false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh058496282023-06-30058496282024-06-30058496282023-07-012024-06-30058496282022-06-30058496282022-07-012023-06-30058496282023-06-3005849628ns15:EnglandWales2023-07-012024-06-3005849628ns14:PoundSterling2023-07-012024-06-3005849628ns10:Director12023-07-012024-06-3005849628ns10:PrivateLimitedCompanyLtd2023-07-012024-06-3005849628ns10:SmallEntities2023-07-012024-06-3005849628ns10:AuditExempt-NoAccountantsReport2023-07-012024-06-3005849628ns10:SmallCompaniesRegimeForDirectorsReport2023-07-012024-06-3005849628ns10:SmallCompaniesRegimeForAccounts2023-07-012024-06-3005849628ns10:FullAccounts2023-07-012024-06-300584962812023-07-012024-06-3005849628ns10:OrdinaryShareClass12023-07-012024-06-3005849628ns10:Director22023-07-012024-06-3005849628ns10:Director32023-07-012024-06-3005849628ns10:Director42023-07-012024-06-3005849628ns10:CompanySecretary12023-07-012024-06-3005849628ns10:RegisteredOffice2023-07-012024-06-3005849628ns5:CurrentFinancialInstruments2024-06-3005849628ns5:CurrentFinancialInstruments2023-06-3005849628ns5:ShareCapital2024-06-3005849628ns5:ShareCapital2023-06-3005849628ns5:RetainedEarningsAccumulatedLosses2024-06-3005849628ns5:RetainedEarningsAccumulatedLosses2023-06-3005849628ns5:IntangibleAssetsOtherThanGoodwill2023-07-012024-06-3005849628ns5:PatentsTrademarksLicencesConcessionsSimilar2023-07-012024-06-3005849628ns5:DevelopmentCostsCapitalisedDevelopmentExpenditure2023-07-012024-06-3005849628ns5:IntangibleAssetsOtherThanGoodwill2023-06-3005849628ns5:IntangibleAssetsOtherThanGoodwill2024-06-3005849628ns5:IntangibleAssetsOtherThanGoodwill2023-06-3005849628ns5:PlantMachinery2023-06-3005849628ns5:PlantMachinery2023-07-012024-06-3005849628ns5:PlantMachinery2024-06-3005849628ns5:PlantMachinery2023-06-3005849628ns5:WithinOneYearns5:CurrentFinancialInstruments2024-06-3005849628ns5:WithinOneYearns5:CurrentFinancialInstruments2023-06-3005849628ns10:OrdinaryShareClass12024-06-30
REGISTERED NUMBER: 05849628 (England and Wales)















Unaudited Financial Statements for the Year Ended 30 June 2024

for

Wilson Bio-chemical Limited

Wilson Bio-chemical Limited (Registered number: 05849628)






Contents of the Financial Statements
for the Year Ended 30 June 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


Wilson Bio-chemical Limited

Company Information
for the Year Ended 30 June 2024







DIRECTORS: Mr T S Wilson
Mr P Metcalf
Mr M Ennis
Mr B Hughes





SECRETARY: Mr T S Wilson





REGISTERED OFFICE: Dunston Innovation Centre
Dunston Road
Chesterfield
South Yorkshire
S41 8NG





REGISTERED NUMBER: 05849628 (England and Wales)





ACCOUNTANTS: Harris & Co Limited
Chartered Accountants
Marland House
13 Huddersfield Road
Barnsley
South Yorkshire
S70 2LW

Wilson Bio-chemical Limited (Registered number: 05849628)

Balance Sheet
30 June 2024

2024 2023
Notes £    £   
FIXED ASSETS
Intangible assets 5 655,242 673,016
Tangible assets 6 3,382 6,679
658,624 679,695

CURRENT ASSETS
Debtors 7 56,401 51,408
Cash at bank and in hand 491,896 222,327
548,297 273,735
CREDITORS
Amounts falling due within one year 8 (2,137,961 ) (1,921,465 )
NET CURRENT LIABILITIES (1,589,664 ) (1,647,730 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

(931,040

)

(968,035

)

CAPITAL AND RESERVES
Called up share capital 9 1,000 1,000
Retained earnings (932,040 ) (969,035 )
SHAREHOLDERS' FUNDS (931,040 ) (968,035 )

Wilson Bio-chemical Limited (Registered number: 05849628)

Balance Sheet - continued
30 June 2024


The Company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 June 2024.

The members have not required the Company to obtain an audit of its financial statements for the year ended 30 June 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the Company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the Company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the Company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Profit and Loss Account has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 27 March 2025 and were signed on its behalf by:





Mr T S Wilson - Director


Wilson Bio-chemical Limited (Registered number: 05849628)

Notes to the Financial Statements
for the Year Ended 30 June 2024

1. STATUTORY INFORMATION

Wilson Bio-chemical Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


The presentation and functional currency of the financial statements is the Pound Sterling (£).

2. STATEMENT OF COMPLIANCE

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006.

3. ACCOUNTING POLICIES

Basis of preparing the financial statements
The financial statements have been prepared on a going concern basis under the historical cost convention. In view of the directors' continued financial support provided to the company, despite the current balance sheet deficit of £968,035 the directors consider that it is appropriate to prepare the company's financial statements on a going concern basis.

Significant judgements and estimates
The principal accounting policies and significant judgements and estimates applied in the preparation of these financial statements are set out below. These policies, judgements and estimates have been consistently applied to all years presented unless otherwise stated.

Turnover
Turnover represents amounts earned on goods and services provided during the year and derives from the provision of goods and services falling within the company's ordinary activities.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Patents and licences are being amortised evenly over their estimated useful life of ten years.

Development costs are being amortised evenly over their estimated useful life of ten years.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

All fixed assets are initially recorded at cost.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Profit and Loss Account, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


Wilson Bio-chemical Limited (Registered number: 05849628)

Notes to the Financial Statements - continued
for the Year Ended 30 June 2024

3. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

4. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 4 (2023 - 5 ) .

5. INTANGIBLE FIXED ASSETS
Other
intangible
assets
£   
COST
At 1 July 2023 746,134
Additions 61,494
At 30 June 2024 807,628
AMORTISATION
At 1 July 2023 73,118
Charge for year 79,268
At 30 June 2024 152,386
NET BOOK VALUE
At 30 June 2024 655,242
At 30 June 2023 673,016

Wilson Bio-chemical Limited (Registered number: 05849628)

Notes to the Financial Statements - continued
for the Year Ended 30 June 2024

6. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
At 1 July 2023
and 30 June 2024 12,521
DEPRECIATION
At 1 July 2023 5,842
Charge for year 3,297
At 30 June 2024 9,139
NET BOOK VALUE
At 30 June 2024 3,382
At 30 June 2023 6,679

7. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Other debtors 56,401 51,408

8. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade creditors 12,452 6,220
Taxation and social security 2,856 -
Other creditors 2,122,653 1,915,245
2,137,961 1,921,465

9. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2024 2023
value: £    £   
1,000 Ordinary £1 1,000 1,000

10. RELATED PARTY DISCLOSURES

Included within other creditors are directors' loan balances of £1,745,618 (2023: £1,745,618).